Published in N Engl J Med on September 29, 1966
Mannan antigenemia in the diagnosis of invasive Candida infections. J Clin Invest (1976) 2.69
Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect Immun (1982) 1.44
Variability of sequential studies of lymphocyte blastogenesis in normal adults. Clin Exp Immunol (1976) 1.40
Clinical heterotransplantation of the liver. Transplant Proc (1970) 1.35
Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Infect Immun (1978) 1.31
Clearance of Candida albicans from the bloodstream of rabbits. Infect Immun (1974) 1.29
Standardization of lymphocyte transformation to Candida immunogen. Clin Exp Immunol (1974) 1.25
In vitro response of human lymphocytes to Mycoplasma pneumoniae. Infect Immun (1972) 1.17
Candida albicans HWP1 gene expression and host antibody responses in colonization and disease. J Med Microbiol (2006) 1.13
Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Infect Immun (1980) 1.01
Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev (1995) 0.91
Ontogeny of human cell-mediated immunity: age-related variation of in vitro infantile lymphocyte transformation. Infect Immun (1976) 0.87
Systemic candidiasis, a diagnostic challenge. Calif Med (1972) 0.86
Chronic pulmonary disease associated with an unusual dysgammaglobulinaemia. Clin Exp Immunol (1968) 0.75
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science (1981) 10.62
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Blindness and visual impairment in southern Malawi. Bull World Health Organ (1986) 6.07
An exploration of the sequence of a 2.9-Mb region of the genome of Drosophila melanogaster: the Adh region. Genetics (1999) 5.87
Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol (1985) 5.67
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med (1969) 4.96
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Increased costs and rates of use in the California workers' compensation system as a result of self-referral by physicians. N Engl J Med (1992) 4.65
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest (1967) 4.45
The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med (1989) 4.41
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Spin warp NMR imaging and applications to human whole-body imaging. Phys Med Biol (1980) 4.05
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Primary immunodeficiencies. Report of a World Health Organization Committee. Pediatrics (1971) 3.69
Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A (1993) 3.66
HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int (1994) 3.60
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Observations of intergranular stress corrosion cracking in a grain-mapped polycrystal. Science (2008) 3.53
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
ISOLATION OF TRICHOMONAS VAGINALIS WITH PENICILLIN. Science (1945) 3.45
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Aberrations of suppressor T cells in human graft-versus-host disease. N Engl J Med (1979) 3.10
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med (1966) 3.03
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity (1998) 2.92
N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol (2001) 2.91
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Hemodynamic regulation: investigation by spectral analysis. Am J Physiol (1985) 2.79
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Heterogeneity of "acquired" or common variable agammaglobulinemia. N Engl J Med (1974) 2.69
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
Sudden infant death syndrome and near sudden infant death syndrome: a review of the literature, 1964 to 1982. Pediatr Clin North Am (1982) 2.63
The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell (1997) 2.57
Fat suppression in MR imaging: techniques and pitfalls. Radiographics (1999) 2.56
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
The opsonic fragment of the third component of human complement (C3). J Exp Med (1975) 2.51
Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol (1996) 2.51
Three-dimensional grain mapping by x-ray diffraction contrast tomography and the use of Friedel pairs in diffraction data analysis. Rev Sci Instrum (2009) 2.49
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Abnormalities of immunoregulatory T cells in disorders of immune function. N Engl J Med (1979) 2.48
Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med (1982) 2.47
AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J (1998) 2.45
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
Implantation of a foetal thymus, restoring immunological competence in a patient with thymic aplasia (Digeorge's syndrome). Lancet (1968) 2.40
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
The spectrum of renal disease in Laurence-Moon-Biedl syndrome. N Engl J Med (1988) 2.36
Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med (1975) 2.35
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med (2001) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
The Columbia University single-ion microbeam. Radiat Res (2001) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology (1999) 2.26
Blindness in the developing world. Br J Ophthalmol (1993) 2.26